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when treated with vancomycin compared with infections
caused by more susceptible MRSA. Aggressive vancomycin
dosing to achieve trough concentrations 15 to 20 $g/ml has
been used to improve outcome when treating infections
caused by MRSA. The clinical utility of this strategy has not
been established; however, aggressive dosing is associated
with nephrotoxicity especially in patients weighing > 101 kg,
with reduced renal function and in intensive care settings.
Using vancomycin in combination with other antimicrobials
has not proven more effective either.
Treatment with other antimicrobials to which MRSA are
susceptible is increasingly used to address concerns regard-
ing the inefﬁcacy of vancomycin therapy for severe MRSA
infections. Clinical trials suggest that linezolid is at least
comparable to vancomycin for treatment of MRSA pneumo-
nia and for pharmacokinetic-pharmacodynamic reasons may
be preferable in selected patients. Daptomycin (6mg/kg/d)
was non-inferior to comparator regimens (low-dose gentam-
icin plus nafcillin or vancomycin) in a clinical trial treating
S. aureus bacteremia and right sided endocarditis; cure
rates were higher with daptomycin compared to vancomycin
(not statistically signiﬁcant) in trial patients with MRSA
bacteremia. Doses of daptomycin (10mg/kg/d) higher than
approved by the FDA are preferred by some experts when
treating MRSA bacteremia or endocarditis. Linezolid has
appeared effective in selected patients with persistent MRSA
bacteremia. Televancin, with dual mechanisms of cidality
versus MRSA, has recently been approved by the FDA for
treatment of complicated skin/soft tissue infection due to
MRSA and may offer additional options for treating severe
infections. New cephalosporins that bind to PBP2’ and to
which MRSA are susceptible are under development and
fusidic acid is attracting increasing interest as an agent for
combination therapy against severe MRSA infections.
doi:10.1016/j.ijid.2010.02.2211
66.003
The potential for a staphylococcal vaccine
O. Schneewind
University of Chicago, Chicago, IL, USA
Staphylococcus aureus is a frequent cause of bac-
teremia, pneumonia, skin and soft tissue infection as
well as osteomyelitis and septic arthritis. The remarkable
pathogenic potential of this microbe has been demon-
strated over the past decade, with the rapid spread of
highly virulent, drug (methicillin)-resistant S. aureus strains
(MRSA). The search for protective immunity against inva-
sive S. aureus disease has been a research goal since the
discovery of this microbe, however this pursuit has not
yet been successful and a staphylococcal vaccine is cur-
rently not available. To identify protective antigens for a
staphylococcal vaccine, three models systems for S. aureus
infections in mice were developed - pneumonia, lethal sep-
ticemia and persistent abscess model. Using a combination
of molecular genetic tools, the genetic requirements of the
pathogen for each of the three disease complexes were char-
acterized. Genes encoding secreted products that proved
to be necessary for the pathogenesis in any one of three
disease models were examined further, subjecting the puri-
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ed products to vaccine trials for protective immunity.
ene products that generated protection were also tested
or cross-protection in other disease models or examined
or speciﬁc animal or human immune responses follow-
ng infection. Taken together these studies revealed that
taphylococci elicit only moderate host immune responses
o infection owing to their expression of several differ-
nt immune-suppressive molecules, in particular adenosine
ynthase AdsA. a-hemolysin was the sole protective anti-
en for staphylococcal lung infection. Antibodies against
eme-iron scavenging factors provided protective immunity
gainst staphylococcal abscess formation, whereas combi-
ations of different antibodies generated protection against
ethal septicemia in mice. These studies therefore suggest
hat the generation of a successful vaccine against S. aureus
nfection requires a combination of different antigens, but
annot be accomplished by a single factor.
oi:10.1016/j.ijid.2010.02.2212
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RSA in Latin America: special considerations
. Guzman-Blanco
Hospital Privado, Caracas, Venezuela
Until the year 2000, epidemiological surveillance in Latin
merica was conducted in only a few countries, includ-
ng Venezuela and Argentina. Since then, with the support
f the Pan American Health Organization (PAHO), a net-
ork for surveillance of bacterial resistance has been
rganized, which includes the majority of Latin American
ountries: the Monitoring/Surveillance Network for Resis-
ance to Antibiotics. Criteria for admission of surveillance
enters to the network include concepts of standardization,
uality control, supervision visits and regular data report-
ng. Results are published each year on the PAHO web site
www.paho.org) .The data are collected during the daily
ork of selected laboratories in the region, with strong sup-
ort from national and regional reference laboratories.
The Resistance Group of the Panamerican Infectious Dis-
ases Asociation, under the leadership of Dr. Jose Maria
asellas has kept surveillance on the incidence of MRSA and
pdated reports are published on the API journal.
The methodology used for deﬁnition of a given strain as
RSA is different in each country. Some countries work with
he Bauer and Kirby method using the oxacillin or cefoxitin
isks, and others use automated methods like VITEK 1 or 2
bioMérieux) and/or MicroScan (Dade Behring).
Conﬁrmation tests such as the methicillin screen plate
est are not widely used. The high cost of E-test strips does
ot permit their routine use in laboratories in the region,
nd rapid methods of mecA gene detection are not available
or the majority of laboratories. Molecular analysis of MRSA
trains is restricted to some centers in Brazil, Argentina,
hile, Mexico and Colombia. In cases of nosocomial out-
reaks, the identity of MRSA strains is usually assumed from
he phenotypic pattern of antibiotic resistance.Nosocomial, multidrug-resistant MRSA is a growing
roblem in Latin America. Information gathered by the
AHO-sponsored program on nosocomial infections demon-
trated that for the year 2004, MRSA prevalence was as
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ollows: Argentina, 42% (n = 5851 isolates); Bolivia, 36%
n = 1167); Chile, 80% (n = 246); Colombia, 47% (n = 4214);
osta Rica, 58% (n = 674); Cuba, 6% (n = 80); Ecuador,
5% (n = 1363); Guatemala, 64% (n = 1483); Honduras, 12%
n = 393); Mexico, 52% (n = 497); Nicaragua, 20% (n = 296);
araguay, 44% (n = 980); Peru, 80% (n = 1407); Uruguay, 59%
n = 1431) and Venezuela, 25% (n = 2114).
Similarly, data submitted to the Pan-American Associa-
ion of Infectious Diseases for the year 2006 showed the
ollowing rates of HA-MRSA: Argentina 51%; Bolivia 55%;
razil 54%; Chile 29%; Ecuador 25%; Mexico 32%; Panama
8%; Paraguay 30%; Uruguay 24%; and Venezuela 27% The
rst published report of CA-MRSA infections in Latin Amer-
ca came from Brazil, where three wellcharacterized strains,
solated from patients with SSTIs or septic arthritis in 2003,
arbored SCCmec type IV, PVL, enterotoxin and #-hemolysin
enes. A further report followed of a large outbreak of CA-
RSA infection that affected inmates in jails and people
rom the community in Montevideo, Uruguay, beginning in
anuary 2002. At the end of the outbreak, more than 1000
atients had been affected and 12 deaths had occurred.
STIs accounted for more than 65% of the cases, but severe
orms of pneumonia were reported, including 4 deaths. In
his outbreak, TMP-SMX was very active in the treatment of
kin infections.
Since those ﬁrst reports, MRSA has been identiﬁed as
he cause of community-acquired infections in several more
ountries across South America. In Lima, 27% resistance
o methicillin was reported in isolates collected from 30
ommunity-acquired infections in 2002. Two cases of SSTI
aused by CA-MRSA strains were reported from Bogotá in
006, and a report from the Colombian network of resistance
urveillance showed an increase in CA-MRSA from 1% of S.
ureus isolates in 2001 to 5.4% in 2006 [21]. The PAHO pro-
ram has also included surveillance of community-acquired
RSA infections since 2005, and in Venezuela, 12.4% of 845
solates of S. aureus from the community were resistant to
xacillin. However, no clinical information is available for
hese cases. A few isolated cases of CA-MRSA infection have
een reported in Chile, but some of these were in peo-
le returning from cities in Uruguay or Brazil with a high
ncidence of MRSA.
MRSA is an increasing problem in Latin America, both
n the healthcare environment and in the community. In
osocomial S. aureus infections, the frequency of methi-
illin resistance has surpassed 50% in over half of the
atin American countries for which data were identiﬁed.
ommunity-acquired-MRSA has been reported in Latin Amer-
ca and even though large outbreaks such as the one that
ccurred in Uruguay — causing 12 deaths — have not been
eported elsewhere, this example highlights the problem.
urveillance programs are only recently beginning to record
A-MRSA, and the true incidence of MRSA in the community
s still largely unknown in the region.
oi:10.1016/j.ijid.2010.02.2213
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icrobial chemical ecology and the future of antibiotics
. Kolter
Harvard Medical School, Boston, MA, USA
When it comes to cell-to-cell communication the pre-
ominant language is that of small signaling molecules. The
icrobial world is no exception - microbes are known to
xchange messages both within and across species by secret-
ng and recognizing small molecule natural products. Among
uch compounds can be found many of the antibiotics that
ave been extensively used in medicine since the middle
f the last century. Concomitant with their use has been
he evolution of antibiotic resistance. In order to under-
tand the phenomenon of antibiotic resistance and to devise
etter strategies for future antibiotic discovery and use it
s useful to consider this topic from an ecological perspec-
ive. In this sense, it is important that to recognize that we
emain largely ignorant of the role that antibiotic substances
lay in environmental settings. Work that I will discuss in
his lecture supports the idea that antibiotics can serve
on-lethal signaling functions in bacteria - both within and
cross species. In addition, I will discuss instances in which
nterspecies interactions mediated by small molecule natu-
al products lead to narrow spectrum action of antibiotics in
cological settings. These results suggest new ways to look
or and use antibiotics in the future.
oi:10.1016/j.ijid.2010.02.2214
uberculosis: Tools for the Future (Invited Presen-
ation)
8.001
nlocking the Mycobacterial Cell Wall: Insights into
irulence, Biosynthetic Pathways and systems-based
pproach to drug discovery
. Verma1, A. Goyal2, R. Sankaranarayanan2, R. Gokhale3,∗
National Institute of Immunology, Delhi, India
Centre for Cellular and Molecular Biology, Hyderabad,
ndia
Institute of Genomics & Integrative Biology, Delhi, India
Biosynthetic machinery of complex lipids in Mycobac-
erium tuberculosis (Mtb) includes a family of FadD proteins,
hich are otherwise universally involved in fatty acid degra-
ation. Mtb produce several exotic lipids, many of which
re important for its virulence as well as survival in the
ost. By combination of structural, genetic and biochem-
cal studies, we have identiﬁed several novel mechanisms
nd pathways that generates complex cell envelope lipids.
e show that polyketide synthase in conjunction with a
ew family of fatty acyl AMP ligases (FAALs) in Mtb are
nvolved in biosynthesis of lipids. Based on the structure
f a FAAL homologue and by generating loss- as well as
ain-of-function mutants, we show that an insertion motif
ictates the synthesis of acyl-adenylates or acyl-CoA, and
hus bifurcates metabolic fate of fatty acids. Since FAALs
